Evidence map›Paper›PMID 37900211›Full record

ReviewWorld journal of hepatology2023

Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms.

Shubhrat Purwar, Anam Fatima, Himashree Bhattacharyya, Lakshmi Venkata Simhachalam Kutikuppala, Matei-Alexandru Cozma, Bahadar Singh Srichawla, Leah Komer, Khulud Mahmood Nurani, Mihnea-Alexandru Găman

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Shubhrat PurwarDepartment of Internal Medicine, Grant Government Medical College, Mumbai 400008, Maharashtra, India.
Anam FatimaDepartment of Internal Medicine, Pandit Jawaharlal Nehru Memorial Medical College, Raipur 492001, Chhattisgarh, India.
Himashree BhattacharyyaDepartment of Community & Family Medicine, AIIMS Guwahati, Assam 781101, India.
Lakshmi Venkata Simhachalam KutikuppalaDepartment of General Surgery, Dr NTR University of Health Sciences, Vijayawada 521104, Andhra Pradesh, India.
Matei-Alexandru CozmaFaculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, Bucharest 050474, Romania.
Bahadar Singh SrichawlaDepartment of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States.
Leah KomerDepartment of Psychiatry, University of Toronto, Toronto M5G 1V7, Ontario, Canada.
Khulud Mahmood NuraniFaculty of Health Sciences, University of Nairobi, Nairobi 30197-00100, Kenya.
Mihnea-Alexandru GămanFaculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, Bucharest 050474, Romania.
Carol Davila University of Medicine and Pharmacy · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The liver has a central role in metabolism, therefore, it is susceptible to harmful effects of ingested medications (drugs, herbs, and nutritional supplements). Drug-induced liver injury (DILI) comprises a range of unexpected reactions that occur after exposure to various classes of medication. Even though most cases consist of mild, temporary elevations in liver enzyme markers, DILI can also manifest as acute liver failure in some patients and can be associated with mortality. Herein, we briefly review available data on DILI induced by targeted anticancer agents in managing classical myeloproliferative neoplasms: Chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, and myelofibrosis.

Indexed as

Chronic myeloid leukemiaDrug-induced liver injuryEssential thrombocythemiaHepatotoxicityMyelofibrosisMyeloproliferative neoplasmsPolycythemia vera

Identifiers

PMID37900211
PMCPMC10600697
OpenAlexW4386922381

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.